TeleMedicine: Remote Treatment of Diabetes; First Program of its Kind Launches in Israel

TeleMedicine: Remote Treatment of Diabetes; First Program of its Kind Launches in Israel

DiaB

According to a study in the Journal of Diabetes Science and Technology [1], telemedicine [an automated support tool for patients with diabetes] can facilitate better decisions by patients and health care providers[2].

 

Telemedicine programs can impact various aspects of patient care, including informational, clinical, behavioral, structural, and economic. The informational impact is a better quality of information than handwritten records, which may be incomplete or inadvertently forgotten at home on appointment days. The clinical impact is a more frequent communication of information and instructions, which can lead to improved outcomes with lower A1C levels or fewer adverse sequelae. The behavioral impact is more frequent therapy adjustments and reminders, leading to greater patient education and empowerment. The structural impact is usually time-saving for patients who might need to come in to the physician’s office for fewer visits. While the Journal indicates that physician workload of reviewing messages and updated data on a regular basis may actually increase; it also takes the burden off of doctor-to-patient ratios if much of the monitoring and treatment is handled remotely. The economic impact of these programs is complex, and needs to be better understood[3].

 

What Are the Goals for Using Telemedicine?

There are four main goals for using telemedicine to collect, transmit, analyze, discuss, and automatically respond to medical data. These reasons all relate to promoting greater effectiveness in the interaction between the patient and the health care provider team.

Telemedicine can facilitate the achievement of individualized treatment goals by

(1) training patients to manage their own disease;

(2) introducing population-based tools for health care, such as individually tailored education modules and registries;

(3) providing access to electronic decision support tools with oversight from physicians; and

(4) delivering timely information and directions based on individual data and population data.

 

Telemedicine & Diabetes

Telemedicine is particularly well suited to treating diabetes, as compared to other diseases, because diabetes requires interpretation and predetermined responses to many types of data that can be measured in the home by the patient. As technology for communication improves, as better data management and decision support software become available, and as payers and regulatory bodies become comfortable with legal and liability issues inherent to this approach to home care, then it is expected that diabetes telemedicine will become increasingly adopted. Telemedicine promises to become a novel 21st-century tool for diabetes health care providers to communicate with patients to improve the quality and lower the costs of health care.

 

Recent Example

Maccabi Healthcare, an HMO in Israel, has introduced a telecare Diabetes Management Solution through its MOMA division. Patients with diabetes are offered a tool called Dario™, which enables laboratory-testing capabilities using smart mobile devices. The Dario™ tool, manufactured by LabStyle, is built to access both real-time and historical blood glucose data; designed to spot patterns; recommend the right treatments; and supports behavior change efforts.  The tool is designed to support informed decisions by patients, doctors and healthcare systems; and also features a self-monitoring system that combines a lancet to obtain a blood sample, a proprietary disposable test strip cartridge and a smartphone-driven glucose meter.

 

Maccabi’s Director of Medical Tele-Centers, Ms. Angela Irony commented, “This is the first program of its kind in Israel and Maccabi is proud to be a leader in implementing and understanding the advantages of remote care for chronic disease like diabetes. The Dario™ is a key part of this platform and has enabled us to extend remote care for the treatment of diabetes.”

 

Through MOMA, Maccabi is now providing chronic diabetes patients a service of advanced multi-disciplinary support and care through a national call center in coordination with the client’s primary physician and other community-based resources. Each MOMA member with diabetes is receiving their own Dario™ smart meter for managing and monitoring their diabetes. Caretakers at call centers now have a direct online view and proactive communication over the Dario™ mobile platform.

 

Press Release Follows

 

LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel

Leveraging Dario’s mobile health technology to improve patient outcomes and healthcare economics; LabStyle generates subscription revenues from digital platform and software subscription

CAESAREA, Israel, May 26, 2015 /PRNewswire/ — LabStyle Innovations Corp. (DRIO), developer of the Dario™ Diabetes Management Solution, announced today that in partnership with Israel’s leading HMO, Maccabi Healthcare, it has launched the comprehensive Dario™ Diabetes Management Solution as part of Maccabi’s advanced Telecare unit (MOMA). The Dario™ is a proprietary customized diabetes management solution that enables remote treatment for diabetes aiming to improve overall outcomes for patients.  Maccabi has integrated the Dario™ into MOMA, leveraging LabStyle’s cutting edge online and mobile healthcare technologies.

 

“By providing a digital platform for remote diabetes behavioral programs, tele-medicine and other meta-data analyses, we are advancing the treatment of a disease that impacts an estimated 387 million people around the world,” stated Erez Raphael LabStyle Innovations, President and Chief Executive Officer.

 

“Through agreements like the one with Maccabi, LabStyle benefits from recurring revenue streams from software licensing, which is a strong complement to the sales of our Dario™ device and associated disposables,” Raphael added.

 

Maccabi’s Director of Medical Tele-Centers, Ms. Angela Irony commented, “This is the first program of its kind in Israel and Maccabi is proud to be a leader in implementing and understanding the advantages of remote care for chronic disease like diabetes. The Dario™ is a key part of this platform and has enabled us to extend remote care for the treatment of diabetes.”

 

Through MOMA, Maccabi is now providing chronic diabetes patients a service of advanced multi-disciplinary support and care through a national call center in coordination with the client’s primary physician and other community-based resources. Each MOMA member with diabetes is receiving their own Dario™ smart meter for managing and monitoring their diabetes. Caretakers at call centers now have a direct online view and proactive communication over the Dario™ mobile platform.

 

Maccabi Healthcare subscribed to LabStyle’s Dario digital platform, as detailed in the previously announced agreement. This subscription business model represents an additional, high-margin revenue stream for LabStyle, including software licensing and added value services offered to HMOs in territories where the Dario™ has received regulatory approval.

 

About Maccabi

Maccabi Healthcare Services, one of the largest non-profit health funds in the world, provides comprehensive medical coverage to 2 million members. Maccabi has long been recognized, both in Israel and abroad, as a unique and innovative health care system that includes all services, leading the way in many areas including cutting edge medical technology, comprehensive and integrated computerized information systems, cost–effective management, and sophisticated monitoring and evaluation tools.

About LabStyle Innovations

LabStyle Innovations Corp. (OTCQB:DRIO) develops and commercializes patented technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle’s flagship product is the Dario™ Diabetes Management Solution. Dario™ empowers people with diabetes to take charge of their health with the right tools, insights, and support in their pocket.  With access to both real-time and historical blood glucose data, Dario™ is designed to spot patterns, recommend the right treatments and support behavior change efforts.  Dario™ is a platform that combines an all-in-one, blood glucose meter, smart phone application (iOS & Android), website application and treatment tools to support more proactive and better informed decisions by patients, doctors and healthcare systems. The stylish and compact self-monitoring system combines a lancet to obtain a blood sample, a proprietary disposable test strip cartridge and a smartphone-driven glucose meter. LabStyle Innovations is led by an experienced management team with vast software, medical device and technology experience and guided by a world class board of directors and scientific advisory board. For more information, please visit www.myDario.com and http://myDario.investorroom.com the content of which is not incorporated by reference into this press release.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the “Company”) related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, forward-looking statements are being used in this press release when we discuss advancing the treatment of diabetes to people around the world, when we discuss the benefits of the agreement with Maccabi Healthcare, or when we discuss recurring revenue streams from software licensing. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals of our products, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of our sales and marketing efforts in North America,, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the “Risk Factors” section and elsewhere in the Company’s annual report on Form 10-K for the year ended December 31, 2014 and in subsequent filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

 

Contacts:

 
Press and Investor Relations  
Brenda Zeitlin

LabStyle Innovations

 
1 800 896 9062  
Brenda@mydario.com  

 

REFERENCES & SOURCES

[1] SOURCE: “Using Telemedicine to Improve Outcomes in Diabetes—An Emerging Technology,” [David C. Klonoff, M.D., FACP: J Diabetes Sci Technol. 2009 Jul; 3(4): 624–628; Published online 2009 Jul.]

[2] REFERENCE: [Telemedicine] Systems have been developed to organize six types of uploaded objective and subjective data of interest to managing diabetes, including (1) patient-collected physiological data, such as blood glucose levels, continuous glucose levels, and blood pressure; (2) laboratory data, such as hemoglobin A1c (A1C) or lipid levels; (3) behavioral information, such as dietary intake and exercise patterns; (4) medication dosages, allergies, and other history; (5) subjective symptoms of hypoglycemia or other complaints; (6) pertinent event data, such as emergency room visits, hospitalizations, scheduled ophthalmology visits, vaccines, and missed clinic appointments; and (7) images of retinal photos, wounds, or other structures. The pattern of information can be analyzed with decision support software. In this way, a midlevel practitioner or a physician can contact the patient either on a scheduled regular response basis if the situation is safe or on an automatic immediate as-needed basis in the event of a high-risk dangerous event. Images of retinal examinations or foot wounds can be transmitted from a generalist’s office to a specialist consultant at a remote central location. In some cases, foot images for remote transmission can even be collected at home by patients themselves. These images can be evaluated either in real time by a physician taking the measurement or soon afterward by a specialist consultant at a remote central location.

[3] Ibid, SOURCE: “Using Telemedicine to Improve Outcomes in Diabetes—An Emerging Technology,” [David C. Klonoff, M.D., FACP: J Diabetes Sci Technol. 2009 Jul; 3(4): 624–628; Published online 2009 Jul.]

[4] SOURCE LabStyle Innovations Corp.

RELATED LINKS

http://www.mydario.com

Leave a Comment